Legal & General Group
IMPL

Legal & General Group’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Legal & General Group’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-510
Closed -$3K – 3713
2022
Q1 		$3K Hold
510
– – ﹤0.01% 3543
2021
Q4 		$4K Hold
510
– – ﹤0.01% 3557
2021
Q3 		$6K Buy
510
+82
+19% +$1.19K ﹤0.01% 3477
2021
Q2 		$4K Buy
+428
New +$5.11K ﹤0.01% 3470

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Legal & General Group's IMPL Position: Q2 2022 in Review

Legal & General Group sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q2 2022, closing a stake of 510 shares — an estimated $3K sold.

Legal & General Group first reported a position in IMPL in Q2 2021 and held it in 4 quarters. The position peaked at $6K in Q3 2021. 36 funds tracked by Wall St. Rank hold IMPL as of Q2 2022.

  • Legal & General Group reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 510 Impel Pharmaceuticals Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Legal & General Group first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Legal & General Group's Impel Pharmaceuticals Inc. Common Stock position peaked at $6K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.